| 1 |
NCT00652899 |
Terminated
Has Results |
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Biological: Allopurinol
- Drug: Cyclophosphamide
- Drug: Fludarabine phosphate
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product
- Number of Patients Per Disease Response
- Median Number of Days to Progression
- Median Overall Survival Number of Days Patients Alive After Treatment
|
14 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00652899 |
2007LS138
UMN-MT2007-19R
UMN-WCC-53
UMN-0712M23462 |
|
March 2008 |
August 2009 |
August 2009 |
April 4, 2008 |
December 28, 2017 |
September 15, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 2 |
NCT00287859 |
Terminated |
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: topotecan hydrochloride
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
5 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00287859 |
2004LS039
UMN-WCC-39 |
|
August 2004 |
December 2006 |
December 2006 |
February 7, 2006 |
November 29, 2017 |
|
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 3 |
NCT00293293 |
Completed
Has Results |
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine |
- Ovarian Cancer
- Peritoneal Primary Cancer
- Fallopian Tube Cancer
|
- Other: healing touch
- Other: massage therapy
- Other: hypnosis
- Drug: Standard chemotherapy
|
Interventional
|
Not Applicable |
- Masonic Cancer Center, University of Minnesota
- Randy Shaver Cancer Research Fund
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Quality of Life Comparison - Average FACT-O Scoring in Chemotherapy Alone vs. Chemotherapy Plus Complementary Alternative Medicine (CAM)
- Comparison of Mental Health Inventory (MHI) Questionnaire Results - Average for Chemotherapy Alone vs. Chemotherapy Plus CAM
- Number of Patients With Delays In Receiving Chemotherapy Alone
- (and 12 more...)
|
43 |
Female |
Child, Adult, Older Adult |
NCT00293293 |
2000NT790
UMN-WCC-30
0012M77821 |
|
May 2005 |
April 2009 |
January 2010 |
February 17, 2006 |
December 28, 2017 |
June 6, 2012 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 4 |
NCT00903630 |
Terminated
Has Results |
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: Lenalidomide
- Drug: liposomal doxorubicin
|
Interventional
|
Phase 1
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Celgene Corporation
- Masonic Cancer Center, University of Minnesota
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 - Maximum Tolerated Dose (MTD) of Lenalidomide When Combined With Fixed Dose Liposomal Doxorubicin in Women With Recurrent Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Phase 1 - Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
- Phase 2 - Number of Subjects Achieving a Partial or Complete Response
- Phase 2 - Number of Subjects Who Are Progression-Free and Alive
|
15 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00903630 |
2008LS047
0805M32463
WCC #50
RV-OVAR-PI-0447 |
|
April 2009 |
August 2011 |
August 2011 |
May 18, 2009 |
December 28, 2017 |
January 18, 2017 |
- University of Minnesota Medical Center - Fairview
Minneapolis, Minnesota, United States
|
|
| 5 |
NCT02118285 |
Completed |
Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Biological: NK cells
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Incyte Corporation
- Masonic Cancer Center, University of Minnesota
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of INCB024360
- Initial tumor response
- Duration of tumor response
- (and 2 more...)
|
2 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02118285 |
2012LS101
MT2013-11 |
|
July 28, 2014 |
November 12, 2015 |
November 12, 2015 |
April 21, 2014 |
December 5, 2017 |
|
- University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
|
|
| 6 |
NCT00331422 |
Terminated
Has Results |
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: paclitaxel
- Procedure: cytoreductive surgery
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients Who Underwent Optimal Cytoreduction After Chemotherapy
- Patients' Overall Tumor Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST)
- Clinical Response Based on Serum Cancer Antigen 125 (CA-125) Concentration
- (and 3 more...)
|
7 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00331422 |
2004LS070
UMN-0409M64006
UMN- WCC-40 |
|
October 2005 |
March 2008 |
March 2009 |
May 31, 2006 |
December 28, 2017 |
February 8, 2010 |
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 7 |
NCT03054909 |
Recruiting |
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer |
- FIGO Stage III and IV Ovarian Cancer
- FIGO Stage III and IV Fallopian Tube Cancer
- FIGO Stage III Primary Peritoneal Cancer
|
- Biological: ALT-803 Subcutaneous
- Biological: ALT-803 Intraperitoneal
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Overall Survival
- ALT-803 associated toxicities
- Incidence of no recorded toxicity grade 3 or greater
|
28 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03054909 |
2016LS034 |
|
September 19, 2017 |
December 31, 2020 |
December 31, 2021 |
February 16, 2017 |
September 26, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 8 |
NCT01144442 |
Completed
Has Results |
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Carcinoma
|
- Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin
- Other: Isotonic saline (perfusate)
- Procedure: Surgery
- (and 2 more...)
|
Interventional
|
Not Applicable |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Response
- Feasibility of HIPC in Recurrent Disease Setting
- Quality of Life Measurements
- (and 2 more...)
|
10 |
Female |
16 Years to 90 Years (Child, Adult, Older Adult) |
NCT01144442 |
2009LS114
WCC# 59
1003M78874 |
|
August 2010 |
September 2012 |
September 2013 |
June 15, 2010 |
March 25, 2016 |
September 5, 2013 |
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 9 |
NCT00536523 |
Terminated |
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Constipation
- Bowel Obstruction
- Fallopian Tube Cancer
- (and 2 more...)
|
|
Observational
|
|
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Alterations in serotonin levels associated with increased constipation
|
13 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00536523 |
2007NT031
WCC-52 |
|
April 2007 |
December 2009 |
December 2009 |
September 28, 2007 |
August 22, 2014 |
|
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 10 |
NCT01626014 |
Completed |
Interactive Educational Website for Women With Ovarian Cancer & Caregivers |
- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Recurrent Ovarian Cancer
- Fallopian Tube Cancer
|
- Behavioral: Usual Care Educational Website
- Behavioral: Prototype System
|
Interventional
|
Early Phase 1 |
- University of Minnesota - Clinical and Translational Science Institute
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Comparison of Number of Women Who Completed Advanced Directive
- Comparison of Number of Women Who Report Appointment with Palliative Care
|
53 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01626014 |
2012NTLS005 |
|
August 2012 |
December 2014 |
December 2014 |
June 22, 2012 |
December 2, 2015 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 11 |
NCT01105650 |
Completed
Has Results |
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Breast Cancer
|
- Drug: Fludarabine
- Drug: Cyclophosphamide
- Drug: Cyclosporine
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Time to Disease Progression
- Number of Participants With Progressive Disease at One Year
- Overall Survival
|
13 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01105650 |
2009LS142
MT2009-30
1003M78876 |
|
July 2010 |
April 2014 |
April 2014 |
April 16, 2010 |
December 28, 2017 |
February 24, 2017 |
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 12 |
NCT03213964 |
Recruiting |
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int |
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
|
- Biological: FATE-NK100
- Drug: Interleukin-2
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Doze of FATE-NK100
- Objective Response Rate
- Progression-Free Survival (PFS)
- Overall Survival (OS)
|
16 |
Female |
18 Years to 75 Years (Adult, Older Adult) |
NCT03213964 |
2016LS186 |
|
October 19, 2017 |
November 1, 2019 |
April 1, 2020 |
July 11, 2017 |
September 26, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
|
| 13 |
NCT01747798 |
Completed |
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
|
- Drug: auranofin
- Other: laboratory biomarker analysis
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of conducting a 10-patient pilot study in asymptomatic ovarian cancer patients using CA 125 elevation
- Immunohistochemical staining for PKCt expression in resected tumor samples with Auranofin
- Patients' perceptions of learning of CA 125 elevation
- Oral gold therapy influence on the CA 125 levels
|
10 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01747798 |
MC1162
NCI-2012-02207 |
|
November 2, 2012 |
January 10, 2014 |
April 6, 2015 |
December 12, 2012 |
October 8, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 14 |
NCT00610740 |
Completed
Has Results |
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer |
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
|
- Drug: topical gemcitabine hydrochloride
- Procedure: therapeutic conventional surgery
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC)
- Number of Patients With Measurable Concentration of Gemcitabine Metabolites in Uterine Vein (dFdU)
- Number of Patients With Measurable Peripheral Vein Concentration of dFdC
|
18 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00610740 |
2005LS071
WCC #44
UMN-0510M6486 |
|
July 2006 |
April 2008 |
April 2008 |
February 8, 2008 |
December 28, 2017 |
June 17, 2010 |
- University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
|
|
| 15 |
NCT03732950 |
Not yet recruiting |
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Jonsson Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) assessed per immune related Response Evaluation Criteria in Solid Tumors (irRECIST)
- Progression-free survival (PFS) assessed per irRECIST
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
30 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03732950 |
18-000643
NCI-2018-01550
P30CA016042 |
|
December 1, 2018 |
December 1, 2019 |
December 1, 2020 |
November 7, 2018 |
November 7, 2018 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 16 |
NCT01606241 |
Completed |
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Breast Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- (and 24 more...)
|
- Drug: Cyclophosphamide
- Other: Laboratory Biomarker Analysis
- Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)
- Disease-free survival
- FRa expression
- (and 2 more...)
|
24 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01606241 |
MC1015
NCI-2012-00586
P30CA015083 |
|
July 24, 2012 |
September 25, 2014 |
March 3, 2018 |
May 25, 2012 |
September 18, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 17 |
NCT00958698 |
Active, not recruiting |
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma
- Psychological Impact of Cancer
- Recurrent Ovarian Carcinoma
|
- Other: Communication Intervention
- Other: Educational Intervention
- Other: Internet-Based Intervention
- (and 3 more...)
|
Interventional
|
Not Applicable |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Symptom severity, symptom-related distress, consequences, and control of symptoms as measured by the Symptom Representation Questionnaire
- Barriers to symptom management as measured by the Symptom Management Barriers Questionnaire
- Communication with health care providers and use of self-care strategies assessed by investigator-developed survey
- (and 3 more...)
|
485 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00958698 |
GOG-0259
NCI-2011-01950
CDR0000648729
U10CA101165 |
|
January 19, 2010 |
January 8, 2017 |
|
August 13, 2009 |
August 31, 2018 |
|
- Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Cedars Sinai Medical Center
Los Angeles, California, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - (and 131 more...)
|
|
| 18 |
NCT02042430 |
Active, not recruiting |
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Stage III Fallopian Tube Cancer AJCC v7
- Stage III Ovarian Cancer AJCC v6 and v7
- Stage III Primary Peritoneal Cancer AJCC v7
- (and 12 more...)
|
- Drug: Epacadostat
- Other: Laboratory Biomarker Analysis
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Early Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with an increase in CD8+ T cells
- Change in number and character of tumor infiltrating lymphocytes
- Change in gene signatures as assessed by microarray analysis
- (and 8 more...)
|
17 |
Female |
19 Years and older (Adult, Older Adult) |
NCT02042430 |
NCI-2013-02483
CITN-05 OVARIAN IDO
ICD 10033159
ICD 10016180
ICD 10026669
CITN-05
P30CA015704
U01CA154967 |
|
December 31, 2013 |
March 31, 2016 |
|
January 22, 2014 |
February 15, 2019 |
|
- University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - Roswell Park Cancer Institute
Buffalo, New York, United States
|
|
| 19 |
NCT02900560 |
Recruiting |
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer |
- Epithelial Ovarian Cancer
|
- Drug: CC-486
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- Translational Research in Oncology
- Celgene
- Translational Research in Oncology
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects with grade 3, 4, or 5 adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03
- Number of subjects with with irPR, irCR or irSD as assessed by irRECIST
- Number of subjects with treatment emergent adverse events as assessed by CTCAE v4.03
|
20 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02900560 |
TRIO026 |
|
December 20, 2016 |
December 2018 |
September 2019 |
September 14, 2016 |
October 15, 2018 |
|
- UCLA
Los Angeles, California, United States - Johns Hopkins University
Baltimore, Maryland, United States - University of Minnesota
Minneapolis, Minnesota, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 20 |
NCT02111941 |
Active, not recruiting |
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Tumor
- Fallopian Tube Mucinous Neoplasm
- (and 20 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
|
Interventional
|
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLT), graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Overall survival (OS)
- Time to disease recurrence (TDR)
|
19 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02111941 |
MC1361
NCI-2014-00713
P30CA015083 |
|
April 14, 2014 |
August 18, 2017 |
December 2019 |
April 11, 2014 |
February 19, 2019 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 21 |
NCT01704651 |
Completed
Has Results |
Accelerating Gastrointestinal Recovery |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
|
- Drug: Alvimopan
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Jamie N. Bakkum-Gamez
- Cubist Pharmaceuticals LLC
- Mayo Clinic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Postoperative Length of Hospital Stay
- Postoperative Ileus Incidence
|
146 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01704651 |
12-004082 |
|
January 2013 |
August 2015 |
October 2015 |
October 11, 2012 |
October 24, 2016 |
October 24, 2016 |
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 22 |
NCT01372787 |
Active, not recruiting |
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
- Anxiety
- Fatigue
- Nausea and Vomiting
- (and 20 more...)
|
- Procedure: Assessment of Therapy Complications
- Other: Medical Chart Review
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
|
- Prevalence and severity of patient-reported symptoms as measured by the NFOSI-18, the FACIT-F subscale, and the FACT/GOG-AD and NTX subscales
|
103 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01372787 |
GOG-0267
NCI-2011-02547
CDR0000701477
U10CA101165 |
|
April 2011 |
January 2014 |
|
June 14, 2011 |
May 8, 2017 |
|
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
Aurora, Colorado, United States - Hartford Hospital
Hartford, Connecticut, United States - Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States - (and 141 more...)
|
|
| 23 |
NCT01167712 |
Active, not recruiting
Has Results |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- (and 27 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Procedure: Computed Tomography
- (and 2 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
- Median Duration of First Quartile Survival
- Quality of Life Score as Measured by Functional Assessment of Cancer Therapy-Ovary-Total Outcome Index (Fact-O TOI)
|
692 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01167712 |
NCI-2011-03812
11-00374
GOG-0262/ACRIN 6695
ACRIN 6695
CDR0000681448
GOG-0262
U10CA180868
U10CA027469 |
|
September 27, 2010 |
December 1, 2015 |
|
July 22, 2010 |
January 3, 2019 |
January 23, 2018 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 571 more...)
|
|
| 24 |
NCT01666444 |
Unknown † |
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
|
- Drug: pegylated liposomal doxorubicin (PLD)
- Drug: VTX-2337
- Drug: Placebo
|
Interventional
|
Phase 2 |
- VentiRx Pharmaceuticals Inc.
- Gynecologic Oncology Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone
- Progression-free survival (PFS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST).
- Frequency and severity of drug-related adverse events (AEs) of patients treated with VTX-2337 + PLD versus those treated with PLD alone.
|
290 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01666444 |
GOG-3003 |
|
October 2012 |
October 2016 |
October 2016 |
August 16, 2012 |
July 22, 2016 |
|
- St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Winthrop P. Rockefeller Cancer Institute - University of Arkansas
Little Rock, Arkansas, United States - Providence Saint Joseph Medical Center
Burbank, California, United States - (and 133 more...)
|
|
| 25 |
NCT00951496 |
Active, not recruiting
Has Results |
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
- Ovarian Brenner Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- (and 19 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Progression-free Survival
- Patients With Adverse Events by Treatment Group, as Defined by NCI CTCAE (Common Terminology Criteria for Adverse Events Version 3.0) Version 3.0
- Overall Survival
- (and 4 more...)
|
1560 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00951496 |
NCI-2011-01956
09-0724
CDR0000650601
GOG-0252
U10CA180868
U10CA027469 |
|
August 11, 2009 |
January 11, 2016 |
|
August 4, 2009 |
February 15, 2019 |
May 18, 2018 |
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 502 more...)
|
|
| 26 |
NCT03038100 |
Recruiting |
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Atezolizumab
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Hoffmann-La Roche
- GOG Foundation
- European Network of Gynaecological Oncological Trial Groups (ENGOT)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population
- PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death−Ligand 1 (PD-L1)−Positive Subpopulation
- Overall Survival - ITT Population
- (and 10 more...)
|
1300 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03038100 |
YO39523
2016-003472-52 |
IMagyn050 |
March 8, 2017 |
April 1, 2020 |
December 1, 2021 |
January 31, 2017 |
February 19, 2019 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - St. Joseph'S Hospital & Medical Center
Phoenix, Arizona, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - (and 377 more...)
|
|
| 27 |
NCT02311907 |
Completed
Has Results |
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
- Chemotherapeutic Agent Toxicity
- Neuropathy
- Neurotoxicity Syndrome
- (and 13 more...)
|
- Drug: Carboplatin
- Drug: Glutathione
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).
- Recurrence-free Survival (for Patients Without Clinical Evidence of Disease)
- Change in Patient Reported Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and Patient Daily-symptom Questionnaires Over Time.
- (and 6 more...)
|
195 |
All |
18 Years and older (Adult, Older Adult) |
NCT02311907 |
N08CA
NCI-2011-01965
CDR0000654097
U10CA037404 |
|
December 2009 |
August 2012 |
August 2012 |
December 9, 2014 |
February 23, 2017 |
February 23, 2017 |
- Providence Hospital
Mobile, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 387 more...)
|
|
| 28 |
NCT02657928 |
Active, not recruiting |
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer |
- Estrogen Receptor Positive
- Postmenopausal
- Recurrent Fallopian Tube Carcinoma
- (and 3 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Letrozole
- Drug: Ribociclib
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients alive and progression-free at 12 weeks
- CA-125 response, defined as a 50% or greater reduction in baseline CA-125
- Confirmed response rate (complete response or partial response) using Response Evaluation Criteria in Solid Tumors version 1.1
- (and 3 more...)
|
40 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02657928 |
MC1561
NCI-2015-02181
P30CA015083 |
|
July 8, 2016 |
June 2021 |
July 2021 |
January 18, 2016 |
May 18, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 29 |
NCT01139957 |
Unknown † |
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer |
- Breast Carcinoma
- Fallopian Tube Carcinoma
- Ovarian Neoplasm
- Primary Peritoneal Carcinoma
|
- Procedure: Evaluation of Cancer Risk Factors
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Procedure: Study of High Risk Factors
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Breast cancer mortality rates
- Ovarian cancer mortality rates
- Prospective incidence of ovarian cancer (including fallopian tube cancer), primary peritoneal cancer, breast cancer, and all cancer
- Quality of life
|
1916 |
Female |
30 Years and older (Adult, Older Adult) |
NCT01139957 |
GOG-8199
NCI-2011-02233
CDR0000674216
U10CA101165 |
|
June 2010 |
December 2015 |
|
June 9, 2010 |
June 8, 2015 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - (and 140 more...)
|
|
| 30 |
NCT02315430 |
Active, not recruiting |
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- (and 2 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Complete or partial objective tumor response, evaluated using the RECIST v1.1
- Incidence of toxicity as assessed by CTCAE v4
- Overall survival
|
34 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02315430 |
NCI-2014-02411
NRG-GY001
U10CA180868 |
|
April 1, 2015 |
April 30, 2019 |
|
December 11, 2014 |
February 6, 2019 |
|
- Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 407 more...)
|
|
| 31 |
NCT00565851 |
Active, not recruiting |
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
- Clear Cell Adenocarcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- (and 15 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Drug: Docetaxel
- (and 4 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer
- To determine if the addition of bevacizumab increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian, peritoneal primary or fallopian tube cancer
- Progression-free survival
- (and 3 more...)
|
1038 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00565851 |
NCI-2009-00587
CDR0000546714
GOG-0213
09-0205
U10CA180868
U10CA027469 |
|
December 6, 2007 |
March 15, 2019 |
|
November 30, 2007 |
February 19, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 717 more...)
|
|
| 32 |
NCT02839707 |
Recruiting |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Undifferentiated Carcinoma
- (and 10 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional
|
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities (DLT) of experimental regimens graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used beginning April 1, 2018)
- Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria (Phase II)
- Overall survival (OS) (Phase III)
- (and 10 more...)
|
488 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02839707 |
NCI-2016-01081
NRG-GY009
U10CA180868
UG1CA189867 |
|
May 12, 2017 |
June 30, 2023 |
June 30, 2023 |
July 21, 2016 |
February 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 729 more...)
|
|
| 33 |
NCT00288275 |
Terminated |
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Progression Free Survival
- Tumor Response
|
256 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00288275 |
PT-301 |
|
July 2004 |
|
October 2012 |
February 7, 2006 |
October 5, 2012 |
|
- University of California
Irvine, California, United States - Kaiser Permanente
Los Angeles, California, United States - Yale University Medical Center
New Haven, Connecticut, United States - (and 33 more...)
|
|
| 34 |
NCT00002538 |
Completed |
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Procedure: laparoscopic surgery
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00002538 |
GOG-9302
CDR0000078530 |
|
September 1993 |
March 2010 |
|
June 10, 2004 |
August 20, 2013 |
|
- USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - Women's Cancer Center
Palo Alto, California, United States - (and 8 more...)
|
|
| 35 |
NCT00262990 |
Completed |
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Neoplasms
|
- Drug: EPO906 (Patupilone)
- Drug: doxorubicin
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer
- To determine the duration of overall response in patients with complete response (CR) or partial response (PR) or stable disease (SD)
- To determine the progression-free survival (PFS) of patients treated with patupilone
- (and 5 more...)
|
829 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00262990 |
CEPO906A2303 |
|
November 2005 |
February 2010 |
|
December 7, 2005 |
May 4, 2012 |
|
- Alaska Cancer Research & Education Center
Anchorage, Alaska, United States - Northern Arizona Hematology & Oncology Associates
Flagstaff, Arizona, United States - Mayo Center for Women's Health
Scottsdale, Arizona, United States - (and 146 more...)
|
|
| 36 |
NCT02312245 |
Recruiting |
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Biological: Bevacizumab
- Drug: Gemcitabine Hydrochloride
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with a confirmed tumor response, defined as complete response or partial response estimated using Response Evaluation Criteria in Solid Tumors 1.1 criteria
- Incidence of adverse events (AE)
- Overall survival (OS)
- (and 2 more...)
|
240 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02312245 |
MC1463
NCI-2014-02399
Mod14-002986-03
P30CA015083 |
|
July 21, 2015 |
June 2020 |
June 2020 |
December 9, 2014 |
July 9, 2018 |
|
- Mayo Clinic
Phoenix, Arizona, United States - Mayo Clinic
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 37 |
NCT01493505 |
Terminated |
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
|
- Drug: AMG 386
- Drug: Paclitaxel
- Drug: AMG 386 Placebo
- Drug: Carboplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival (OS)
- Incidence of adverse events and significant laboratory abnormalities
- (and 6 more...)
|
1015 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01493505 |
20101129
TRINOVA-3 20101129/ENGOT-ov2 |
|
January 2012 |
March 2016 |
December 2016 |
December 16, 2011 |
February 23, 2017 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Mobile, Alabama, United States - Research Site
Anchorage, Alaska, United States - (and 307 more...)
|
|
| 38 |
NCT01366183 |
Active, not recruiting |
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
- Stage I Ovarian Cancer
- Stage IA Fallopian Tube Cancer
- Stage IB Fallopian Tube Cancer
- (and 13 more...)
|
- Procedure: Assessment of Therapy Complications
- Drug: Carboplatin
- Biological: Filgrastim
- (and 4 more...)
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
|
- Percent of women, who are 70 years or older, able to complete at least 4 cycles of treatment regardless of dose reduction and delays
- Tolerance to study treatment, defined as completing four cycles of study treatment, without dose reductions or treatment delays of over seven days
- Changes in comorbidity index measured by the Charlson scale
- (and 4 more...)
|
290 |
All |
75 Years and older (Older Adult) |
NCT01366183 |
GOG-0273
NCI-2011-02900
U10CA101165 |
|
August 2011 |
December 2019 |
|
June 3, 2011 |
May 8, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Gynecologic Oncology Group of Arizona
Phoenix, Arizona, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 355 more...)
|
|
| 39 |
NCT00003634 |
Unknown † |
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 2 |
- AltaRex
- National Cancer Institute (NCI)
|
Industry |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
400 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00003634 |
CDR0000066718
ALTAREX-OVA-Gy-07
ALTAREX-961452
ALTAREX-OVA-Gy-06
NCI-V98-1488 |
|
April 1998 |
|
|
September 13, 2004 |
November 6, 2013 |
|
- Alta Bates Comprehensive Cancer Center
Berkeley, California, United States - USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States - Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States - (and 43 more...)
|
|
| 40 |
NCT00004934 |
Completed |
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer
|
- Drug: carboplatin
- Drug: epirubicin hydrochloride
- Drug: paclitaxel
- Procedure: conventional surgery
|
Interventional
|
Phase 3 |
- Nordic Society for Gynaecologic Oncology
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Older Adult) |
NCT00004934 |
CDR0000067620
NSGO-OC9804
CAN-NCIC-OV14
EORTC-55981 |
|
August 1999 |
|
May 2003 |
January 27, 2003 |
February 4, 2013 |
|
- St. Mary's/Duluth Clinic Cancer Center
Duluth, Minnesota, United States - U.Z. Gasthuisberg
Leuven, Belgium - Tom Baker Cancer Center - Calgary
Calgary, Alberta, Canada - (and 15 more...)
|
|
| 41 |
NCT02283658 |
Active, not recruiting |
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Cystadenocarcinoma
- (and 6 more...)
|
- Drug: Everolimus
- Other: Laboratory Biomarker Analysis
- Drug: Letrozole
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients alive and PFS12
- CA-125 response, defined as a 50% or greater reduction in baseline CA-125
- Confirmed response rate, estimated using RECIST 1.1 criteria
- (and 3 more...)
|
20 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02283658 |
MC1464
NCI-2014-02203
P30CA015083 |
|
November 2014 |
November 2018 |
November 2018 |
November 5, 2014 |
March 6, 2018 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 42 |
NCT00108745 |
Active, not recruiting |
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- (and 24 more...)
|
- Other: Clinical Observation
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Frequency and severity of adverse effects assessed by CTCAE v3.0
- Progression-free survival
- Quality of life assessed by Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity version 4
|
1100 |
Female |
Child, Adult, Older Adult |
NCT00108745 |
GOG-0212
NCI-2009-00586
CDR0000422427
U10CA180868
U10CA027469 |
|
March 2005 |
January 2022 |
|
April 19, 2005 |
May 8, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Tennessee Valley Gynecologic Oncology
Huntsville, Alabama, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 304 more...)
|
|
| 43 |
NCT01540565 |
Completed |
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- BRCA1 Mutation Carrier
- BRCA2 Mutation Carrier
- Ovarian Epithelial Tumor
- (and 3 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Veliparib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The frequency of patients who have objective tumor response
- Incidence of adverse effects as assessed by CTCAE v 4.0
- Duration of PFS
- (and 2 more...)
|
52 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01540565 |
NCI-2012-00684
S12-02446
GOG-0280
CDR0000726699
U10CA180868
U10CA027469 |
|
April 9, 2012 |
January 27, 2018 |
January 27, 2018 |
February 29, 2012 |
October 3, 2018 |
|
- Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - John Muir Medical Center-Concord Campus
Concord, California, United States - UC San Diego Moores Cancer Center
La Jolla, California, United States - (and 150 more...)
|
|
| 44 |
NCT00262847 |
Completed
Has Results |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- (and 24 more...)
|
- Biological: Bevacizumab
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-free Survival
- Overall Survival
- Frequency and Severity (Grade 3 or Above) of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0
- Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)
|
1873 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00262847 |
NCI-2009-00590
CDR0000455114
GOG-0218
U10CA180868
U10CA027469 |
|
September 2005 |
November 2010 |
April 2015 |
December 7, 2005 |
October 17, 2018 |
September 18, 2013 |
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Clearview Cancer Institute
Huntsville, Alabama, United States - (and 629 more...)
|
|
| 45 |
NCT00003120 |
Completed |
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission |
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer
|
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
|
308 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00003120 |
CDR0000065875
SWOG-S9701
GOG-178
U10CA032102 |
|
November 1997 |
June 2003 |
November 2012 |
February 20, 2004 |
October 9, 2014 |
|
- MBCCOP - Gulf Coast
Mobile, Alabama, United States - CCOP - Greater Phoenix
Phoenix, Arizona, United States - Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, United States - (and 90 more...)
|
|
| 46 |
NCT02470585 |
Active, not recruiting |
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Ovarian Cancer
- Ovarian Neoplasm
|
- Drug: Veliparib
- Drug: Paclitaxel
- Drug: Carboplatin
- Other: Placebo
|
Interventional
|
Phase 3 |
- AbbVie
- Gynecologic Oncology Group
- Australia New Zealand Gynaecological Oncology Group
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Progression-Free survival (PFS)
- Overall Survival (OS)
- Disease Related Symptom (DRS) scores
|
1140 |
Female |
18 Years to 99 Years (Adult, Older Adult) |
NCT02470585 |
M13-694
2014-005070-11 |
|
July 14, 2015 |
April 4, 2019 |
May 28, 2020 |
June 12, 2015 |
October 18, 2018 |
|
- University of Alabama /ID# 138087
Birmingham, Alabama, United States - Tennessee Valley Gyn-Onc /ID# 139548
Huntsville, Alabama, United States - University of South Alabama /ID# 138091
Mobile, Alabama, United States - (and 211 more...)
|
|
| 47 |
NCT01080521 |
Completed |
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy |
- Cognitive Side Effects of Cancer Therapy
- Malignant Ovarian Epithelial Tumor
- Ovarian Brenner Tumor
- (and 51 more...)
|
- Procedure: Cognitive Assessment
- Other: Quality-of-Life Assessment
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Cognitive function as measured by the HeadMinder Customized Research Tool (CRT)
- Patient-reported cognitive function as measured by Patient Assessment Own Functioning scale and web CRT
|
247 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01080521 |
GOG-0256
NCI-2011-02213
CDR0000666786
U10CA101165 |
|
April 2010 |
January 2012 |
January 27, 2018 |
March 4, 2010 |
April 12, 2018 |
|
- University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - (and 179 more...)
|
|
| 48 |
NCT00721162 |
Completed
Has Results |
Study of Ramucirumab in Ovarian Cancer |
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6)
- Objective Response Rate (ORR): Percentage of Participants With Complete Response (CR) and Partial Response (PR)
- Progression-Free Survival (PFS)
- (and 3 more...)
|
60 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00721162 |
13923
2007-006717-17
CP12-0711
I4T-IE-JVBR |
|
August 2008 |
May 2012 |
August 2015 |
July 23, 2008 |
October 3, 2016 |
June 18, 2014 |
- ImClone Investigational Site
Hollywood, Florida, United States - ImClone Investigational Site
Orlando, Florida, United States - ImClone Investigational Site
Chicago, Illinois, United States - (and 10 more...)
|
|
| 49 |
NCT00719303 |
Recruiting |
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- (and 30 more...)
|
- Behavioral: Behavioral Dietary Intervention
- Behavioral: Compliance Monitoring
- Other: Counseling
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Progression-free survival
- Change in irritable bowel syndrome-specific symptoms measured using GSRS-IBS
- Change in self-reported quality of life measured using RAND-36
|
1070 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00719303 |
GOG-0225
NCI-2009-00595
CDR0000594600
U10CA101165
U10CA180830
UG1CA189867 |
|
June 18, 2012 |
December 31, 2020 |
|
July 21, 2008 |
February 16, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Tennessee Valley Gynecologic Oncology
Huntsville, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 684 more...)
|
|
| 50 |
NCT01891344 |
Active, not recruiting |
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
- Ovarian Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
|
|
Interventional
|
Phase 2 |
- Clovis Oncology, Inc.
- Foundation Medicine
- Myriad Genetics, Inc.
- Clovis Oncology, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Progression (RECIST v1.1) as assessed by investigator, or death from any cause, in molecularly-defined subgroups identified by a prospectively defined HRD signature (PART 1)
- ORR by RECIST v1.1 (PART 2)
- ORR by RECIST v1.1 (PART 1)
- (and 6 more...)
|
493 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01891344 |
CO-338-017 |
ARIEL2 |
September 2013 |
June 2019 |
|
July 3, 2013 |
May 15, 2018 |
|
- Providence Alaska Medical Center
Anchorage, Alaska, United States - University of Arizona Cancer Center
Tucson, Arizona, United States - Saint Jude Heritage Medical Center
Fullerton, California, United States - (and 72 more...)
|
|
| 51 |
NCT00954174 |
Active, not recruiting |
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
- Mixed Mesodermal (Mullerian) Tumor
- Ovarian Carcinosarcoma
- Recurrent Fallopian Tube Carcinoma
- (and 39 more...)
|
- Drug: Carboplatin
- Drug: Ifosfamide
- Drug: Paclitaxel
- Other: Quality-of-Life Assessment
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Duration of progression-free survival
- Incidence of adverse events as assessed by CTCAE version 3.0
- Quality of life measured using the Functional Assessment of Cancer Therapy (FACT)-general, Physical Well-being and Functional Well-being subscales, FACT-endometrial, and FACT/GOG-NTtx subscale
|
603 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00954174 |
GOG-0261
NCI-2011-01959
CDR0000651458
U10CA180868
U10CA027469 |
|
August 17, 2009 |
November 1, 2018 |
|
August 7, 2009 |
January 10, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 523 more...)
|
|
| 52 |
NCT01281254 |
Terminated |
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) |
- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cancer
|
- Drug: AMG386 plus PLD
- Drug: Placebo plus PLD
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by progression-free survival, defined as the time from randomization to the earliest of the dates of first radiologic disease progression per RECIST 1.1 with modifications
- • To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by overall survival
|
223 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01281254 |
20060517
2009-017946-30
ENGOT-ov-6
TRINOVA-2 |
|
April 18, 2011 |
August 29, 2014 |
April 19, 2017 |
January 21, 2011 |
December 2, 2017 |
|
- Research Site
Los Angeles, California, United States - Research Site
San Francisco, California, United States - Research Site
Norwalk, Connecticut, United States - (and 103 more...)
|
|
| 53 |
NCT02354586 |
Active, not recruiting |
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens |
|
|
Interventional
|
Phase 2 |
- Tesaro, Inc.
- Facing Our Risk of Cancer Empowered
- Myriad Genetics, Inc.
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate antitumor activity of niraparib
- Evaluate durability of anti-cancer activity (i.e. time from first response, CR or PR until disease progression).
- Evaluate antitumor activity of niraparib in HRD+ and gBRCAmut
- (and 4 more...)
|
500 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02354586 |
PR-30-5020-C |
QUADRA |
March 2015 |
October 2017 |
December 2019 |
February 3, 2015 |
October 22, 2018 |
|
- Chandler, Arizona, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- (and 46 more...)
|
|
| 54 |
NCT01306032 |
Completed
Has Results |
Phase II ABT-888 With Cyclophosphamide |
- Ovarian Cancer
- Primary Peritoneal Cancer
- Serous Carcinoma Cancer
- (and 2 more...)
|
- Drug: ABT-888
- Drug: Cyclophosphamide
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With an Overall Response Rate
- Progression Free Survival
- Number of Participants With Adverse Events
- (and 3 more...)
|
124 |
All |
18 Years and older (Adult, Older Adult) |
NCT01306032 |
110080
11-C-0080 |
|
January 12, 2011 |
December 31, 2014 |
December 15, 2016 |
March 1, 2011 |
April 26, 2017 |
May 25, 2016 |
- University of California, Davis
Davis, California, United States - H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States - University of Chicago
Chicago, Illinois, United States - (and 7 more...)
|
|
| 55 |
NCT03079687 |
Approved for marketing |
Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. |
|
|
Expanded Access
|
|
|
Industry |
|
|
|
Female |
18 Years to 120 Years (Adult, Older Adult) |
NCT03079687 |
D0816R00014 |
|
|
|
|
March 14, 2017 |
October 25, 2017 |
|
- Research Site
Duarte, California, United States - Research Site
Newport Beach, California, United States - Research Site
Roseville, California, United States - (and 10 more...)
|
|
| 56 |
NCT02446600 |
Active, not recruiting |
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- BRCA Rearrangement
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- (and 13 more...)
|
- Drug: Carboplatin
- Drug: Cediranib Maleate
- Drug: Gemcitabine Hydrochloride
- (and 6 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- AstraZeneca
- National Cancer Institute (NCI)
|
NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival determined using Response Evaluation Criteria in Solid Tumors version 1.1 criteria
- Overall survival
- Frequency and severity of adverse effects
- Patient reported scores of disease-related symptoms as measured by the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 Disease-Related Symptom-Physical
|
549 |
Female |
19 Years and older (Adult, Older Adult) |
NCT02446600 |
NCI-2015-00606
NRG-GY004
s16-01480
U10CA180868 |
|
February 4, 2016 |
December 31, 2019 |
|
May 18, 2015 |
February 15, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 356 more...)
|
|
| 57 |
NCT00381888 |
Completed
Has Results |
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 5 more...)
|
- Drug: fondaparinux sodium
|
Interventional
|
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Venous Thromboembolism at Week 4
- Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.
|
44 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00381888 |
CDR0000503985
UMN-2006LS009
UMN-0603M82707 |
|
January 2007 |
January 2009 |
January 2009 |
September 28, 2006 |
December 28, 2017 |
January 27, 2010 |
- Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States - Crozer-Chester Medical Center
Upland, Pennsylvania, United States
|
|
| 58 |
NCT02983799 |
Recruiting |
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status |
- Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate, defined as the percentage of subjects with a best overall response of confirmed complete response (CR) or partial response (PR)
- Duration of response, for those subjects with a confirmed response of CR or PR
- CA-125 response rate, defined as the percentage of subjects with a CA-125 response according to GCIG criteria divided by the number of subjects evaluable for CA-125 response
- (and 5 more...)
|
260 |
Female |
18 Years to 130 Years (Adult, Older Adult) |
NCT02983799 |
D0816L00003 |
|
December 22, 2016 |
May 21, 2020 |
May 21, 2020 |
December 6, 2016 |
January 14, 2019 |
|
- Research Site
Anchorage, Alaska, United States - Research Site
La Jolla, California, United States - Research Site
Los Angeles, California, United States - (and 48 more...)
|
|
| 59 |
NCT01846611 |
Completed
Has Results |
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Fallopian Tube Neoplasms
|
- Drug: Trabectedin
- Drug: DOXIL
- Drug: Dexamethasone
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
- PharmaMar
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression-Free Survival (PFS)
- Objective Response Rate (ORR)
|
581 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01846611 |
CR100983
ET743OVC3006
2012-004808-34 |
|
October 16, 2013 |
January 18, 2018 |
November 16, 2018 |
May 3, 2013 |
February 6, 2019 |
February 6, 2019 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- (and 140 more...)
|
|
| 60 |
NCT01749397 |
Active, not recruiting |
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7
|
- Drug: Floxuridine
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Veliparib
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Incidence of adverse events
- Incidence of toxicities assessed using CTCAE version 4.0
- (and 8 more...)
|
102 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01749397 |
NCI-2012-02767
MC1114
9182
P30CA015083
P50CA136393
U01CA069912
UM1CA186686
UM1CA186691 |
|
December 7, 2012 |
January 16, 2019 |
|
December 13, 2012 |
November 7, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - Mayo Clinic
Rochester, Minnesota, United States - (and 2 more...)
|
|
| 61 |
NCT02502266 |
Recruiting |
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Fallopian Tube Clear Cell Adenocarcinoma
- (and 14 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- (and 4 more...)
|
Interventional
|
Phase 2
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) (Phase II and Phase III)
- Overall survival (OS) (Phase III)
- Objective response rate (partial or complete response) (Phase II and Phase III)
- Incidence of adverse events (Phase II and Phase III)
|
680 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02502266 |
NCI-2015-00651
s16-01681
NRG-GY005
U10CA180868 |
|
February 5, 2016 |
June 30, 2023 |
|
July 20, 2015 |
February 19, 2019 |
|
- Alaska Women's Cancer Care
Anchorage, Alaska, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 316 more...)
|
|
| 62 |
NCT02059265 |
Active, not recruiting |
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Estrogen Receptor Negative
- Ovarian Clear Cell Cystadenocarcinoma
- (and 4 more...)
|
- Drug: Dasatinib
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with objective tumor response rate (complete response [CR] or partial response [PR]) using RECIST version 1.1
- Duration of overall survival (OS)
- Duration of progression-free survival (PFS)
- Incidence of adverse effects as assessed by Common Terminology Criteria for Adverse Events version 4.0
|
35 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02059265 |
NCI-2014-00209
GOG-0283
U10CA180868
U10CA027469 |
|
February 2014 |
January 2017 |
|
February 11, 2014 |
May 5, 2017 |
|
- Alaska Women's Cancer Care
Anchorage, Alaska, United States - Anchorage Oncology Centre
Anchorage, Alaska, United States - Katmai Oncology Group
Anchorage, Alaska, United States - (and 220 more...)
|
|
| 63 |
NCT03522246 |
Recruiting |
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
- Epithelial Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancer
- (and 4 more...)
|
- Drug: Rucaparib
- Drug: Nivolumab
- Drug: Placebo Oral Tablet
- Drug: Placebo IV Infusion
|
Interventional
|
Phase 3 |
- Clovis Oncology, Inc.
- Bristol-Myers Squibb
- Gynecologic Oncology Group
- (and 3 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Investigator assessed Progression-free survival (PFS)
- Blinded independent central review (BICR) PFS
- Overall Survival (OS)
- (and 5 more...)
|
1012 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03522246 |
CO-338-087/GOG-3020/ENGOT-ov45 |
ATHENA |
May 14, 2018 |
December 30, 2024 |
December 30, 2030 |
May 11, 2018 |
February 7, 2019 |
|
- Arizona Oncology Associates, PC - HAL
Phoenix, Arizona, United States - Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States - The University of Arizona Cancer Center
Tucson, Arizona, United States - (and 87 more...)
|
|
| 64 |
NCT00287885 |
Completed |
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer |
- Cervical Cancer
- Endometrial Cancer
- Fallopian Tube Cancer
- (and 5 more...)
|
|
Interventional
|
Phase 1 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose
- Response to Treatment
- Pharmacokinetics
|
18 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00287885 |
2003LS034
UMN-WCC-35
0307M50626 |
|
March 2004 |
December 2008 |
December 2008 |
February 7, 2006 |
November 29, 2017 |
|
|
|
| 65 |
NCT00445887 |
Completed
Has Results |
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer |
|
- Other: Laboratory Biomarker Analysis
- Drug: Levonorgestrel
- Other: Placebo
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue
- Number of Participants With Adverse Events According to Grade as Determined by NCI CTCAE v.3.0
- Proportion of Proliferation as Measured by Ki-67
- Patients With High Expression of Transforming Growth Factor-beta 1
|
64 |
Female |
30 Years and older (Adult, Older Adult) |
NCT00445887 |
GOG-0214
NCI-2009-00588
CDR0000532268
U10CA101165 |
|
March 2008 |
December 2012 |
|
March 9, 2007 |
January 11, 2018 |
January 11, 2018 |
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States - University of California San Diego
San Diego, California, United States - (and 51 more...)
|
|
| 66 |
NCT02345265 |
Active, not recruiting |
Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Fallopian Tube Endometrioid Adenocarcinoma
- (and 7 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- (and 2 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Objective response rate (platinum-resistant cohort)
- Biomarker signature development
- (and 4 more...)
|
72 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02345265 |
NCI-2015-00051
16-700
9825
UM1CA186644
UM1CA186686
UM1CA186690
UM1CA186691
UM1CA186704
UM1CA186709
UM1CA186712
UM1CA186716
UM1CA186717
ZIABC011078 |
|
December 4, 2015 |
February 1, 2019 |
|
January 26, 2015 |
February 15, 2019 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 17 more...)
|
|
| 67 |
NCT01767675 |
Recruiting |
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Ovarian Cancer
- Fallopian Tubes Cancer
- Peritoneal Cancer
|
- Procedure: Secondary Cytoreductive Surgery
- Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Drug: platinum-based systemic chemotherapy postoperatively
|
Interventional
|
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Mayo Clinic
- Baptist Health South Florida
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- determine the proportion of patients who are without evidence of disease progression
- To determine the toxicity and postoperative complications rate
- determine the completion rate of four cycles
- pharmacokinetics
|
98 |
Female |
21 Years and older (Adult, Older Adult) |
NCT01767675 |
12-275 |
|
January 8, 2013 |
January 2020 |
January 2020 |
January 14, 2013 |
February 6, 2019 |
|
- Hartford Healthcare Cancer Institute @ Hartford Hospital
Hartford, Connecticut, United States - Baptist Health South Florida
Miami, Florida, United States - University of Chicago Medical Center
Chicago, Illinois, United States - (and 8 more...)
|
|
| 68 |
NCT01685255 |
Terminated |
A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy |
- Ovarian Cancer
- Genitourinary (GU) Tumors
|
- Drug: INCB024360
- Drug: tamoxifen
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 definition of progression as determined by the investigator.
- Safety and tolerability of INCB024360 by adverse event assessment.
- Cancer Antigen (CA) 125 response rate, using Gynaecologic Cancer Intergroup (GCIG) criteria.
- (and 2 more...)
|
83 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01685255 |
INCB 24360-210 |
|
August 2012 |
October 23, 2014 |
October 23, 2014 |
September 14, 2012 |
March 26, 2018 |
|
- La Jolla, California, United States
- Los Angeles, California, United States
- San Francisco, California, United States
- (and 46 more...)
|
|
| 69 |
NCT02498600 |
Active, not recruiting |
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1
- Progression-free survival (PFS) hazard ratio
- Duration of overall survival (OS)
- Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (beginning April 1, 2018)
|
96 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02498600 |
NCI-2014-02424
NRG-GY003
9698
U10CA180868 |
|
June 29, 2015 |
December 31, 2020 |
|
July 15, 2015 |
February 6, 2019 |
|
- Sutter Auburn Faith Hospital
Auburn, California, United States - Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States - Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - (and 203 more...)
|
|
| 70 |
NCT01716715 |
Active, not recruiting |
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Frequency of adverse events, defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, graded according to the National Cancer Institute (NCI) CTCAE version 4.0
- Severity of adverse events, defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, graded according to the NCI CTCAE version 4.0
- (and 4 more...)
|
102 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01716715 |
NCI-2012-02058
GOG-0186K
S13-00312
U10CA180868
U10CA027469 |
|
November 6, 2012 |
October 1, 2018 |
|
October 30, 2012 |
September 28, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - John Muir Medical Center-Concord Campus
Concord, California, United States - (and 170 more...)
|
|
| 71 |
NCT01199263 |
Active, not recruiting |
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- Biological: Pelareorep
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Frequency and severity of adverse events as assessed by CTCAE version 4.0
- Median PFS by treatment group
- (and 2 more...)
|
110 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01199263 |
NCI-2011-02654
CDR0000684693
GOG-0186H
U10CA180868
U10CA027469 |
|
December 6, 2010 |
September 1, 2019 |
|
September 10, 2010 |
February 15, 2019 |
|
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, United States - Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California, United States - Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States - (and 33 more...)
|
|
| 72 |
NCT02760849 |
Recruiting |
The Women Choosing Surgical Prevention (WISP) Trial |
- Hereditary Breast and Ovarian Cancer Syndrome
|
- Procedure: Salpingectomy
- Procedure: Oophorectomy
- Behavioral: Questionnaires
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- American Association for Cancer Research
- Dana-Farber Cancer Institute
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in Sexual Function in Interval Salpingectomy with Delayed Oophorectomy (ISDO) Participants
- Change in Sexual Function in Risk-Reducing Salpingo-Oophorectomy (RRSO) Participants
|
300 |
Female |
30 Years to 50 Years (Adult) |
NCT02760849 |
2015-0814
SU2C-AACR-DT16-15
NCI-2016-00778 |
|
May 2016 |
May 2041 |
May 2042 |
May 4, 2016 |
July 10, 2018 |
|
- University of Chicago
Chicago, Illinois, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Mayo Clinic
Rochester, Minnesota, United States - (and 5 more...)
|
|
| 73 |
NCT02595892 |
Recruiting |
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
- Ovarian Serous Tumor
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Drug: ATR Kinase Inhibitor M6620
- Drug: Gemcitabine Hydrochloride
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall response rate (ORR), defined as the percentage of subjects achieving a response rating of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) guideline version (v)1.1
- Clinical benefit rate (CBR), defined as the percentage of subjects achieving a response rating of stable disease >= 4 months, partial response (PR), or complete response (CR)
- (and 5 more...)
|
70 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02595892 |
NCI-2015-01910
16-724
9944
UM1CA186709 |
|
August 25, 2016 |
September 2, 2019 |
|
November 4, 2015 |
February 6, 2019 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - UC San Diego Moores Cancer Center
La Jolla, California, United States - (and 14 more...)
|
|
| 74 |
NCT00770536 |
Completed |
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR |
- Cancer
- Carcinoma
- Fallopian Tube Cancer
- (and 6 more...)
|
- Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
- Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin
- Drug: B1: AMG 386 10 mg/kg + Topotecan
- Drug: B3: AMG 386 15mg/kg + Topotecan
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective is to identify the incidence of adverse events and clinical laboratory abnormalities defined as dose limiting toxicity in subjects treated with AMG 386 + pegylated liposomal doxorubicin (cohort A) and with AMG 386 + topotecan
- To evaluate the treatment effect as measured by: objective response rate (ORR), duration of response (DOR), PFS, change in tumor burden, CA 125 Response and Progression by GCIG and CA-125 duration of response
- To evaluate the incidence of adverse events and clinical laboratory abnormalities not defined as DLTs.
- (and 2 more...)
|
103 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00770536 |
20070182 |
|
January 2009 |
January 2012 |
June 2015 |
October 10, 2008 |
September 29, 2015 |
|
- Research Site
Tucson, Arizona, United States - Research Site
Sacramento, California, United States - Research Site
Orlando, Florida, United States - (and 13 more...)
|
|
| 75 |
NCT02020707 |
Recruiting |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers |
- Cervical Adenosarcoma
- Cervical Adenosquamous Carcinoma
- Cervical Carcinosarcoma
- (and 30 more...)
|
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Other: Pharmacological Study
|
Interventional
|
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of AB-complex, defined as the highest dose level among those under consideration where at most 1 of 6 patients develops a dose-limiting toxicity
- Overall survival (OS)
- Progression-free survival (PFS)
- Tumor response, defined as complete response or partial response on 2 consecutive evaluations at least 8 weeks apart assessed by Response Evaluation Criteria in Solid Tumors
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT02020707 |
MC1371
NCI-2013-01782
P30CA015083 |
|
February 3, 2014 |
June 2025 |
June 2025 |
December 25, 2013 |
December 12, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 76 |
NCT00102973 |
Completed |
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer |
|
- Drug: TLK286 in Combination with Carboplatin
- Drug: Doxorubicin HCl Liposome Injection
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
244 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00102973 |
TLK286.3024 |
|
December 2004 |
July 2008 |
July 2008 |
February 7, 2005 |
May 31, 2012 |
|
- Little Rock Hematology Oncology
Little Rock, Arkansas, United States - Arkansas Oncology Associates
Little Rock, Arkansas, United States - Little Rock Hematology Oncology
Little Rock, Arkansas, United States - (and 219 more...)
|
|
| 77 |
NCT00719212 |
Completed
Has Results |
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer |
|
|
Interventional
|
Phase 2 |
- Translational Research in Oncology
- Translational Research in Oncology
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST Criteria and GCIG CA125 Response Criteria. - Assessments of the Response by the Investigators
- Objective Response Rate (ORR) Independent Radiology Committee % of Patients in the Group Who Achieve a Complete or Partial Response According to RECIST Criteria and GCIG CA 125 Response Criteria.
- Time To Progression (TTP) Investigator Assessment
- (and 4 more...)
|
61 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00719212 |
TRIO 015 |
|
January 2009 |
May 2013 |
May 2013 |
July 21, 2008 |
January 11, 2016 |
December 1, 2015 |
- Comprehensive Blood and Cancer Center
Bakersfield, California, United States - St Jude Heritage Healthcare
Fullerton, California, United States - Wilshire Oncology Medical Group Inc
La Verne, California, United States - (and 34 more...)
|
|
| 78 |
NCT00718523 |
Terminated
Has Results |
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer |
|
- Drug: AMG 479
- Drug: AMG 479 Placebo
|
Interventional
|
Phase 2 |
- Translational Research in Oncology
- Translational Research in Oncology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS): Time From Randomization Until Date of Progression or Death.
- Time To Progression (TTP): Interval From the Date of Randomization to the Date of Disease Progression
- Overall Survival (OS)
|
170 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00718523 |
TRIO 014 |
|
January 2009 |
September 2013 |
November 2014 |
July 18, 2008 |
January 12, 2016 |
January 12, 2016 |
- Central Hematology Oncology Medical Group Inc.
Alhambra, California, United States - Providence Saint Joseph Medical Center
Burbank, California, United States - St Jude Heritage Healthcare
Fullerton, California, United States - (and 52 more...)
|
|
| 79 |
NCT00191646 |
Completed
Has Results |
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
- Genital Neoplasms, Female
- Fallopian Tube Neoplasms
- Ovarian Neoplasms
- (and 2 more...)
|
- Drug: Gemcitabine
- Drug: Paclitaxel
- Drug: Carboplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Proportion of Participants With Response (Response Rate)
- Time to Treatment Failure
- Overall Survival
|
919 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00191646 |
6891
B9E-US-S302 |
|
October 2002 |
August 2009 |
August 2009 |
September 19, 2005 |
March 4, 2011 |
September 9, 2010 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Little Rock, Arkansas, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Los Gatos, California, United States - (and 52 more...)
|
|
| 80 |
NCT01012817 |
Active, not recruiting |
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer |
- Metastatic Malignant Solid Neoplasm
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- (and 2 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacogenomic Study
- Other: Pharmacological Study
- (and 2 more...)
|
Interventional
|
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of topotecan hydrochloride and veliparib, determined according to incidence of dose-limiting toxicity, graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Proportion of tumor responses, defined as complete response or partial response as assessed using Response Evaluation Criteria In Solid Tumors
- Overall survival
- (and 4 more...)
|
102 |
All |
18 Years and older (Adult, Older Adult) |
NCT01012817 |
NCI-2011-00312
MC0861
MAYO-MC0861
CDR0000657976
09-000742
8329
P30CA015083
P50CA083639
P50CA136393
UM1CA186686 |
|
October 29, 2009 |
August 31, 2020 |
|
November 13, 2009 |
February 6, 2019 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 12 more...)
|
|
| 81 |
NCT01010126 |
Completed
Has Results |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
- Adult Hepatocellular Carcinoma
- Advanced Adult Hepatocellular Carcinoma
- Endometrial Serous Adenocarcinoma
- (and 42 more...)
|
- Biological: Bevacizumab
- Drug: Temsirolimus
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival Rate
- Tumor Response Rate
- Duration of Response
- (and 4 more...)
|
252 |
All |
18 Years and older (Adult, Older Adult) |
NCT01010126 |
NCI-2012-02086
NCI-2011-02504
MC0845
CDR0000653790
NCI-2012-01049
8233
N01CM00032
N01CM00038
N01CM00039
N01CM00070
N01CM00071
N01CM00099
N01CM00100
N01CM62201
N01CM62203
N01CM62204
N01CM62205
N01CM62206
N01CM62207
N01CM62208
N01CM62209
P30CA015083
P50CA102701 |
|
September 8, 2009 |
March 13, 2017 |
March 13, 2017 |
November 9, 2009 |
January 25, 2019 |
January 25, 2019 |
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Tower Cancer Research Foundation
Beverly Hills, California, United States - City of Hope Comprehensive Cancer Center
Duarte, California, United States - (and 58 more...)
|
|
| 82 |
NCT02657889 |
Active, not recruiting |
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer |
- Triple Negative Breast Cancer
- Ovarian Cancer
- Breast Cancer
- (and 5 more...)
|
- Drug: niraparib
- Biological: pembrolizumab
|
Interventional
|
Phase 1
Phase 2 |
- Tesaro, Inc.
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate dose-limiting toxicities (DLTs) of combination treatment with niraparib and pembrolizumab during the first cycle of treatment, and to establish a recommended Phase 2 dose (RP2D) and schedule
- To estimate the clinical activity of combination treatment with niraparib and pembrolizumab in terms of objective response rate (ORR) as assessed by the Investigators using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- To evaluate the safety and tolerability of combination treatment with niraparib and pembrolizumab using Common Terminology Criteria for Adverse Events (CTCAE, v4.03)
- (and 12 more...)
|
121 |
All |
18 Years and older (Adult, Older Adult) |
NCT02657889 |
3000-PN162-01-001 |
TOPACIO |
March 2016 |
May 2018 |
February 2019 |
January 18, 2016 |
February 12, 2018 |
|
- Birmingham, Alabama, United States
- Scottsdale, Arizona, United States
- Scottsdale, Arizona, United States
- (and 27 more...)
|
|
| 83 |
NCT02364713 |
Recruiting |
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
- Fallopian Tube Transitional Cell Carcinoma
- Malignant Ovarian Clear Cell Tumor
- Malignant Ovarian Endometrioid Tumor
- (and 9 more...)
|
- Drug: Gemcitabine Hydrochloride
- Other: Laboratory Biomarker Analysis
- Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- (and 4 more...)
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Incidence of adverse events per Common Terminology Criteria for Adverse Events version 4.0
- Objective response rates defined to be a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart
- (and 2 more...)
|
134 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02364713 |
MC1365
NCI-2015-00133
P30CA015083 |
|
March 13, 2015 |
February 2025 |
February 2025 |
February 18, 2015 |
October 26, 2018 |
|
- Mayo Clinic
Phoenix, Arizona, United States - Mayo Clinic
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
| 84 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Older Adult) |
NCT02834013 |
NCI-2016-01041
S1609
U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
February 18, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 868 more...)
|
|
| 85 |
NCT00897442 |
Completed |
Collecting Tumor Samples From Patients With Gynecological Tumors |
- Borderline Ovarian Clear Cell Tumor
- Borderline Ovarian Serous Tumor
- Cervical Adenocarcinoma
- (and 83 more...)
|
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collection of gynecological tumor specimens and serum from patients at GOG institutions
- Create a repository for long-term storage of these specimens
- Make available tissue and blood for proposed projects
|
275 |
Female |
Child, Adult, Older Adult |
NCT00897442 |
GOG-0136
NCI-2009-00577
GOG-136
CDR0000078647
U10CA180868 |
|
June 1992 |
January 2016 |
|
May 12, 2009 |
October 28, 2016 |
|
- Highlands Oncology Group PA - Fayetteville
Fayetteville, Arkansas, United States - Washington Regional Medical Center - Fayetteville
Fayetteville, Arkansas, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 184 more...)
|
|
| 86 |
NCT02315469 |
Active, not recruiting |
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery |
- Endometrial Serous Adenocarcinoma
- Fallopian Tube Carcinoma
- Ovarian Carcinoma
- (and 6 more...)
|
- Other: Comprehensive Geriatric Assessment
- Other: Questionnaire Administration
|
Observational
|
|
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
|
- GA-GYN score, defined as the summation of the risk score for each risk factor derived from the predictive model including 5 risk factors from the GA and 3 other risk factors
- Occurrence of major post-operative complications outlined in The American College of Surgeons? National Surgical Quality Improvement Program
- Comorbidity, as measured by the Older American Resources and Services (OARS) Physical Health section
- (and 11 more...)
|
190 |
Female |
70 Years and older (Older Adult) |
NCT02315469 |
NRG-CC002
NCI-2014-01376
GOG-ELD1301
U10CA101165
UG1CA189867 |
|
February 10, 2015 |
March 15, 2016 |
|
December 11, 2014 |
February 16, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - (and 390 more...)
|
|
| 87 |
NCT02032823 |
Recruiting |
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer |
|
- Drug: Olaparib
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Breast International Group
- Frontier Science & Technology Research Foundation, Inc.
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Invasive Disease Free Survival (IDFS)
- Overall survival (OS)
- Distant Disease Free Survival (DDFS)
- (and 4 more...)
|
1800 |
All |
18 Years to 130 Years (Adult, Older Adult) |
NCT02032823 |
D081CC00006
NSABP B-55
BIG 6-13 |
OlympiA |
April 22, 2014 |
November 30, 2020 |
November 27, 2028 |
January 10, 2014 |
December 11, 2018 |
|
- Research Site
Anchorage, Alabama, United States - Research Site
Anchorage, Alaska, United States - Research Site
Anchorage, Alaska, United States - (and 1306 more...)
|
|
| 88 |
NCT03170960 |
Recruiting |
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Non-Small Cell Lung Cancer
- (and 10 more...)
|
- Drug: cabozantinib
- Drug: atezolizumab
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Escalation: MTD/Recommended Dose
- Dose Expansion: ORR
- Incidence and severity of nonserious AEs and SAEs (Safety)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03170960 |
XL184-021 |
|
September 5, 2017 |
March 2020 |
December 2020 |
May 31, 2017 |
February 7, 2019 |
|
- Exelixis Clinical Site #18
Phoenix, Arizona, United States - Exelixis Clinical Site #1
Duarte, California, United States - Exelixis Clinical Site #20
La Jolla, California, United States - (and 24 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: